Six months after receipt of the second Covaxin dose, participants received booster dose of the same. The trial demonstrated long-term safety with no serious events
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study. Neutralizing antibodies in children on an average 1.7 times higher than in adults
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
The approval of shelf life extension is based on the availability of additional stability data, which was submitted to the CDSCO
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
This approval of shelf-life extension was based on the availability of additional stability data, which was submitted to CDSCO
This is the eighth Covid-19 vaccine to receive Emergency Use Listing
The WHO chief scientist Soumya Swaminathan tweeted on Oct. 17
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)